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Abstract
Background: IL-10 has a potent inhibitory effect on osteoclastogenesis. In vitro and in vivo studies
confirm the importance of this cytokine in bone metabolism, for instance IL-10-deficient mice
develop the hallmarks of osteoporosis. Although it is known that IL-10 directly inhibits
osteoclastogenesis at an early stage, preventing differentiation of osteoclast progenitors to
preosteoclasts, the precise mechanism of its action is not yet clear. Several major pathways regulate
osteoclastogenesis, with key signalling genes such as p38, TRAF6, NF-κB and NFATc1 well
established as playing vital roles. We have looked at gene expression in eleven of these genes using
real-time quantitative PCR on RNA extracted from RANKL-treated RAW264.7 monocytes.
Results: There was no downregulation by IL-10 of DAP12, FcγRIIB, c-jun, RANK, TRAF6, p38, NF-
κB, Gab2, Pim-1, or c-Fos at the mRNA level. However, we found that IL-10 significantly reduces
RANKL-induced NFATc1 expression. NFATc1 is transcribed from two alternative promoters in
Mus musculus and, interestingly, only the variant transcribed from promoter P1 and beginning with
exon 1 was downregulated by IL-10 (isoform 1). In addition, immunofluorescence studies showed
that IL-10 reduces NFATc1 levels in RANKL-treated precursors and suppresses nuclear
translocation. The inhibitory effect of IL-10 on tartrate-resistant acid phosphatase-positive cell
number and NFATc1 mRNA expression was reversed by the protein kinase C agonist phorbol
myristate acetate, providing evidence that interleukin-10 disrupts NFATc1 activity through its
effect on Ca2+ mobilisation.
Conclusion: IL-10 acts directly on mononuclear precursors to inhibit NFATc1 expression and
nuclear translocation, and we provide evidence that the mechanism may involve disruption of Ca2+
mobilisation. We detected downregulation only of the NFATc1 isoform 1 transcribed from
promoter P1. This is the first report indicating that one of the ways in which IL-10 directly inhibits
osteoclastogenesis is by suppressing NFATc1 activity.
Background
Osteoclasts are terminally differentiated TRAP-positive
cells derived from monocyte-macrophage lineage precur-
sors and are responsible for bone resorption. The process
of osteoclast formation includes the proliferation and the
differentiation of osteoclast progenitors into mononu-
clear preosteoclasts and the fusion of preosteoclasts into
multinucleated osteoclasts. Excessive osteoclast activity
plays a role in the development of several debilitating dis-
orders such as osteoporosis, rheumatoid arthritis, and
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osteolytic metastases, and so it is vital that osteoclast
development and function is properly regulated.
Some of the signalling pathways that contribute to osteo-
clast differentiation have started to emerge. Signalling by
RANKL, an osteoblast-expressed member of the tumour
necrosis factor superfamily, is essential for terminal differ-
entiation of monocytes into osteoclasts. Resorptive stim-
uli initiate osteoclast formation by promoting the
expression of osteoblastic RANKL, which binds to its
receptor RANK. Binding of RANKL to RANK recruits sev-
eral signalling intermediates including NF-κB, which is
redistributed to the nucleus by TRAF family intermediates
[1], and NFATc1, which induce the transcription of genes
involved in osteoclast differentiation. NFATc1 is critical to
osteoclast formation [2,3].
Negative regulators of RANKL signalling exist, including
osteoprotegerin, a soluble decoy receptor for RANKL, and
IFN-β, a negative regulator of transcription factor c-Fos
expression [4]. Several cytokines, including IFN-γ, IL-4,
and another tumour necrosis factor family member,
TRAIL, interfere with the ability of RANKL to induce oste-
oclast differentiation. There is rapid degradation of TRAF6
abolishing signalling in the case of IFN-γ [5]. In the case
of IL-4, signal transducer and activator of transcription 6
appears to be a key upstream regulatory molecule [6-9]. In
the case of TRAIL, the mechanism is related to inhibition
of the p38/MAPK pathway via reduced p38/MAPK phos-
phorylation [10].
IL-10 is a potent anti-inflammatory cytokine that sup-
presses both immunoproliferative and inflammatory
responses. It is produced primarily from T cells and acti-
vated macrophages and acts on the macrophage lineage.
Animal studies implicate IL-10 in the development and
progression of arthritis [11-14] and chronic colitis
[15,16]. IL-10 has a critical role in the in vivo regulation
of pro-inflammatory cytokine levels [13,14,17]. It func-
tions in a negative feedback loop, in which it suppresses
the release of inflammatory cytokines and dampens the
acute inflammatory response.
IL-10 also has potent inhibitory effects on osteoclastogen-
esis [18], but the molecular basis of its action is poorly
understood. IL-10 inhibits the early stages of osteoclas-
togenesis, preventing differentiation of osteoclast progen-
itors to preosteoclasts. It has been shown to mediate this
action through both direct and indirect actions. IL-10
indirectly inhibits bone resorption by upregulating osteo-
protegerin expression while downregulating expression of
RANKL and macrophage colony stimulating factor [19].
IL-10 also directly inhibits osteoclast formation [20]. It
was found that the inhibitory effect of IL-10 on osteoclast
formation is mediated through a direct action on osteo-
clast precursors [20,21]. Furthermore, enhanced osteo-
clastogenesis has been observed in cultures of bone
marrow macrophages deficient in IL-10 production [22].
However, the molecular mechanism mediating this direct
effect is unknown.
IL-10-deficient mice are now available and results from
these mice confirm the importance of this cytokine in
bone metabolism. They have been shown to develop the
hallmarks of osteoporosis, namely, reduced bone mass,
increased mechanical fragility, and suppressed bone for-
mation [23]. IL-10 is an important endogenous suppres-
sor of infection-stimulated bone resorption in vivo, and it
appears that the anti-osteoclastic mechanisms induced by
IL-10 on bone are more effective than those mediated by
IL-4 [24]. IL-10-deficient mice exhibit significantly higher
levels of periodontal alveolar bone loss than a matched
control group [25]. This increased alveolar bone loss
appears to be a late onset condition, and analysis of serum
levels of type I collagen C-telopeptide suggests that lack of
IL-10 may have a direct effect on bone homeostasis [26].
Clinical studies back up the theoretical importance of this
work: an IL-10 promoter gene polymorphism has been
found that is associated with reduced bone mineral den-
sity and predisposes women to osteoporosis at the lumbar
spine [27].
In this paper we set out to learn more about how inter-
leukin-10 directly inhibits the process of osteoclastogene-
sis by looking at its effects on selected gene expression in
RAW264.7, a murine monocytic cell line.
Results
IL-10 suppresses osteoclast formation
Three groups of RAW264.7 cells were set up – an
untreated control group, a group treated with RANKL, and
a final group treated with RANKL plus IL-10. As shown
previously, after five days numerous mono and multinu-
clear TRAP-positive cells were seen in the RANKL-treated
cultures. The percentage of TRAP-stained cells in each
group was determined by light microscopy and it was
found that IL-10 significantly inhibits osteoclast forma-
tion but does not abolish it completely (Figure 1). These
results indicate that IL-10 acts directly on monocytes to
inhibit osteoclast differentiation.
NFATc1 is downregulated by IL-10
RANKL was found to induce the expression of NFATc1
mRNA approximately 8-fold, and this was significantly
suppressed by co-incubation with IL-10 (Figure 2). This is
in keeping with the direct action of IL-10 on osteoclast
formation. NFATc1 expression was not however com-
pletely abolished. Isoforms of NFATc1 are known to exist
in both humans [28] and mice [29]. These isoforms are
transcribed from two separate promoters, which can beBMC Cell Biology 2007, 8:4 http://www.biomedcentral.com/1471-2121/8/4
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arbitrarily designated P1 and P2. Transcripts beginning
from P1 start with exon 1 (isoform 1) and are longer than
those beginning from P2 and starting with exon 2 (iso-
form 2). It is possible to design primers to differentiate
between these variants and we did this. We found that
RAW264.7 cells express both NFATc1 isoforms (isoform
1: 7.5 × 103 copies, isoform 2: 3.4 × 102 copies) and
RANKL induced a significant 14.5-fold increase in isoform
1 expression, which IL-10 suppressed (Figure 2B). In con-
trast RANKL and IL-10 had little effect on the expression
of isoform 2 (Figure 2C). Therefore, it appears that IL-10
may suppress osteoclastogenesis by blunting expression
of NFATc1 isoform 1 rather than isoform 2. Because
NFATc1 is central to osteoclast formation, any change in
its expression would be expected to have a major effect on
downstream gene expression.
Expression of other osteoclast signalling genes is 
unaffected
None of the other osteoclast signalling genes tested –
RANK, TRAF6, p38, NF-κB, c-Fos, c-jun, FcγRIIB, DAP12,
Gab2, and Pim1 – were upregulated as strongly as NFATc1
by RANKL, and none of them were downregulated by IL-
10 (data not shown). The key signalling factors known to
trigger NFATc1 expression are TRAF6 and c-Fos [2], and so
the lack of response of these genes in our experiments sug-
gests that the effect of IL-10 on monocytes is not mediated
through these pathways, in which case it must be medi-
ated through an alternative mechanism.
IL-10 alters cellular localisation of NFATc1
NFATc1 is the most strongly induced transcription factor
gene following RANKL stimulation [2,3]. RANKL also
evokes Ca2+ oscillations that lead to calcineurin-mediated
activation of NFATc1. In resting T cells NFATc1 is
restricted to the cytoplasm. Following T-cell activation, a
sustained increase in intracellular calcium activates the
phosphatase calcineurin. The activated calcineurin
dephosphorylates NFATc1 and leads to increased nuclear
accumulation. Therefore it was of interest to determine
the cellular location of NFATc1 in the RANKL- and IL-10-
treated monocytes. In keeping with our qPCR results,
RANKL-treated cells showed intense cytoplasmic staining
and nuclear accumulation was also noted (Figure 3). Sim-
ilarly, again in keeping with our qPCR results, IL-10
reduced the intensity of cytoplasmic staining and little
nuclear accumulation was observed in these cultures. This
correlates with NFATc1 being highly active in the RANKL-
treated cells and less active in the presence of IL-10.
IL-10 may disrupt NFATc1 activity through its effect on 
Ca2+ mobilisation
PKC plays a critical role in T cell receptor-induced NFAT
activation [30]. Deficiency of PKC primarily abrogates
NFAT transactivation. This NFAT defect appears to be sec-
ondary to reduced inositol 1,4,5-triphosphate generation
and intracellular Ca2+ mobilisation. Since we had not
found any effect of IL-10 on TRAF6 or c-Fos, we wanted to
see if we could find any evidence that IL-10 is acting
through its effects on Ca2+ mobilisation, and this was
done using the PKC agonist PMA. Cells were treated with
RANKL, RANKL plus IL-10, and RANKL plus IL-10 plus
PMA, and viewed under the microscope. The suppressive
effect of IL-10 was abolished by PMA treatment, as deter-
mined by extent of TRAP staining (Figure 4). Quantitative
PCR results were in agreement, with PMA reversing the
inhibitory effect of IL-10 on NFATc1 expression (Table 1).
Discussion
IL-10 is an anti-inflammatory cytokine that suppresses
both immunoproliferative and inflammatory responses.
It is produced primarily from T cells and activated macro-
phages. Animal studies implicate IL-10 in the develop-
ment and progression of arthritis and chronic colitis. IL-
10 has a critical role in the in vivo regulation of pro-
inflammatory cytokine levels. It functions in a negative
feedback loop, in which it suppresses the release of
inflammatory cytokines and dampens the acute inflam-
matory response. Clinical studies and IL-10-deficient mice
back up the theoretical importance of this work, as dis-
cussed in the introduction. IL-10 has been known for
Osteoclast formation is suppressed by IL-10 Figure 1
Osteoclast formation is suppressed by IL-10. 
RAW264.7 cells were incubated with RANKL or RANKL 
plus IL-10 for 5 days. All cytokine concentrations were 50 ng/
ml. Cells were fixed and stained for TRAP and the number of 
TRAP-positive mono and multinuclear osteoclasts quantified. 
Results are expressed as the mean ± SEM for each group 
from three separate experiments. IL-10 significantly sup-
pressed osteoclast formation. * p < 0.05 versus control, ** p 
< 0.05 versus RANKL-treated group.
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NFATc1 expression is suppressed by IL-10 Figure 2
NFATc1 expression is suppressed by IL-10. RAW264.7 cells were incubated with cytokines (RANKL 50 ng/ml and IL-10 
50 ng/ml) for 2 days and total RNA extracted. NFATc1 expression was assessed using quantitative PCR using specific primers 
recognising both isoforms (A) isoform 1 (B) or isoform 2 (C). Results are expressed as the mean ± SEM for each group from 
three separate experiments normalised for β-actin. * p < 0.05 versus control, ** p < 0.05 versus RANKL-treated group.
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some time to have a potent inhibitory effect on osteoclas-
togenesis [18]. It prevents differentiation of osteoclast
progenitors to preosteoclasts, however its mechanism of
action is still unclear.
We have studied the expression of eleven osteoclast sig-
nalling genes and have found that one of the ways in
which IL-10 directly inhibits osteoclastogenesis is by dis-
rupting NFATc1 mRNA expression and nuclear transloca-
tion. NFATc1 is crucial for osteoclastogenesis, and so its
downregulation may be expected to have major down-
stream effects. We also provide evidence that this disrup-
tion to NFATc1 may be mediated through the effect of IL-
10 on Ca2+ mobilisation. In addition, it was found that
only NFATc1 isoform 1 transcribed from promoter P1 was
downregulated by IL-10.
Osteoclast formation was not abolished in the presence of
IL-10 and similarly NFATc1 levels did not revert to basal
level in the IL-10 treated cells. Several pathways contrib-
ute to induction of NFATc1 levels and it may well be the
case that IL-10 does not inhibit all of them. The initial
IL-10 reduces NFATc1 immunostaining intensity and nuclear translocation Figure 3
IL-10 reduces NFATc1 immunostaining intensity and nuclear translocation. NFATc1 staining was noted in the cyto-
plasm and nuclei of RANKL treated RAW264.7 cells (B and C), whereas only weak cytoplasmic staining was observed in 
RANKL + IL-10 treated cells (D.) No staining was noted in control cultures (A). Photographs taken at a magnification of × 400 
A, B, D and ×1000 C.
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expression of NFATc1 is dependent on both the TRAF6
and c-Fos pathways, which are unaffected by IL-10.
RANKL stimulation also results in the induction of Ca2+
oscillations which activate NFATc1 via a calcineurin-
dependent mechanism, targeting it to the nucleus [2]. For
the generation of osteoclasts it has been demonstrated
that the high NFATc1 levels generated by autoregulation
are necessary for cell lineage commitment [reviewed in
[31]]. Therefore the reduction in levels, rather than com-
plete abrogation, brought about by IL-10 will be sufficient
to cause the potent inhibition of osteoclastogenesis
shown in these studies.
There are two variants of NFATc1 in Mus musculus but only
one of these, isoform1, was downregulated by IL-10. It is
not known why the shorter isoform 2 is not similarly
modified by IL-10. This may in part be related to the rela-
tive inability of RANKL to induce the expression of iso-
form 2 in RAW cells, or it could be that the conformation
of the DNA is such that IL-10-induced transcription fac-
tors only have access to the P1 promoter. Linked in with
this, it is likely that the finding that NFATc1 expression
was not completely abolished is due to a combination of
residual expression from the P1 promoter and the inabil-
ity of IL-10 induced factors to suppress basal expression
from the P2 promoter. Alternatively, it could also be that
IL-10 acts only on a subset of the various pathways that
contribute to NFATc1 upregulation.
The activity of NFATc1 is not only dependent on its level
of expression, but also its location within the cell. It is
active only when in the nucleus, as would be expected of
a transcription factor. This nuclear transport relies upon
active calcineurin which triggers dephosphorylation of
NFATc1. Therefore we used antibodies to establish the
intracellular distribution of NFATc1. The fact that very lit-
tle staining, and in particular nuclear staining, was
observed in the IL-10 sample strengthens our evidence
that the inhibitory effect of IL-10 on osteoclastogenesis
can be explained at least in part by its effect on NFATc1
expression and activity.
PKC plays a critical role in T cell receptor-induced NFAT
activation [30]. Deficiency of PKC primarily abrogates
NFAT transactivation. This NFAT transactivation defect
appears to be secondary to reduced inositol 1,4,5-triphos-
phate generation and intracellular Ca2+  mobilisation.
Therefore, we set out to test whether IL-10 is disrupting
NFATc1 activity through its effect on Ca2+ mobilisation.
We found that PMA inhibits the suppressive effect of IL-10
on osteoclast formation, as determined by TRAP staining
and NFATc1 expression. PMA is an activator of PKC, and
so if PMA is overcoming the suppressive effects of IL-10,
knowing how PMA acts it would appear that IL-10 is dis-
rupting NFATc1 activity through its effect on Ca2+ mobili-
PMA inhibits the suppressive effect of IL-10 on osteoclast  formation Figure 4
PMA inhibits the suppressive effect of IL-10 on osteo-
clast formation. RAW264.7 cells were incubated with 
RANKL, IL-10 or PMA for 3 days. Cultures were washed to 
remove PMA and then incubated for a further two days with 
RANKL or RANKL + IL-10. Cells were fixed and stained for 
TRAP and the number of TRAP-positive mono and multinu-
clear osteoclasts quantified. IL-10 suppressed the number of 
TRAP positive cells and this was prevented by PMA. Results 
are expressed as the mean ± SEM for each group from three 
separate experiments n = 9. * p < 0.05 versus all other 
groups.
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Table 1: Effect of PMA on IL-10 induced suppression of NFATc1
Group NFATc1 copies per 106 β-actin ± SEM Relative change in expression compared to 
RANKL group
CONTROL 8.5 × 103 ± 3 × 103 * 0.006 *
RANKL 1.4 × 106 ± 5 × 105 0
RANKL + IL-10 4.6 × 104 ± 1 × 104 * 0.032 *
RANKL + IL-10 + PMA 7.9 × 105 ± 9 × 104 0.56
Quantitative RT-PCR analysis of NFATc1 mRNA expression in RAW264.7 cells. Cultures were treated with RANKL, RANKL and IL-10 or 
RANKL, IL-10 and PMA for 24 hours and total RNA extracted. Quantitative PCR was performed on a Techne Quantica PCR machine using the 
DNA binding dye SYBR-green and specific primers for murine NFATc1 and β-actin. For each sample the NFATc1 copy number was expressed as 
the relative copy number normalised to 106 β-actin copies. Samples were analysed in triplicate and are expressed as the mean of three separate 
experiments. * p < 0.05 versus RANKL group.BMC Cell Biology 2007, 8:4 http://www.biomedcentral.com/1471-2121/8/4
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sation. Therefore the effect of IL-10 could involve PKC as
PMA reverses the suppressive action of IL-10.
The mechanism by which IL-10 interferes with osteoclast
formation appears to be different from that used by other
inhibitors, namely IFN-γ, IL-4, and TRAIL. IL-4 also down-
regulates NFATc1 but it acts through suppression of c-Fos
[32], we did not find any evidence for c-Fos being down-
regulated although it remains possible that it could be
inactivated by other means. IFN-γ causes rapid degrada-
tion of TRAF6 protein; we found no difference in TRAF6
mRNA levels but did not look at protein levels. Likewise,
TRAIL interferes with the p38 pathway and there was no
downregulation of p38 mRNA in IL-10 treated cultures.
It is valuable to pinpoint the effect of IL-10 on osteoclast
signalling pathways since evidence is accumulating, par-
ticularly from studies of IL-10-deficient mice, to illustrate
the importance of this cytokine in bone homeostasis. We
have demonstrated that one of the ways by which IL-10
directly inhibits osteoclast formation is to suppress
NFATc1 expression and activation. In vivo, IL-10 may be
expected to have an even more pronounced effect due to
its indirect action of suppressing RANKL expression [19]
which would further reduce NFATc1 activation through
TRAF6. This is the first report indicating that one of the
ways in which IL-10 inhibits osteoclastogenesis is by sup-
pressing NFATc1 activity.
Conclusion
IL-10 acts directly on mononuclear precursors to inhibit
NFATc1 expression and nuclear translocation, and we
provide evidence that the mechanism may involve disrup-
tion of Ca2+ mobilisation. We detected downregulation
only of the NFATc1 isoform transcribed from promoter P1
and beginning with exon 1. This is the first report indicat-
ing that one of the ways in which IL-10 directly inhibits
osteoclastogenesis is by suppressing NFATc1 activity.
Methods
Cell culture and cytokines
RAW264.7 cells were maintained in Dulbecco's modified
Eagle's medium with 10% heat-inactivated fetal calf
serum. They were transferred to a 24-well plate for
cytokine addition and plated at a concentration of 105
cells per well. Cultures were fed every 2–3 days. TRAP
staining (see below) was used to determine the extent of
osteoclast formation. Cytokines were obtained from
Insight Biotechnology (Wembley, UK). RANKL was added
to cells to give a final concentration of 50 ng/ml, IL-10 was
added to give a final concentration of 50–100 ng/ml.
TRAP cytochemistry
Osteoclast formation was evaluated by quantification of
TRAP-positive cell number using a modification of the
method of Burstone [33]. After incubation, coverslips
were washed in phosphate-buffered saline, fixed in 10%
formalin for 10 min, and stained for acid phosphatase in
the presence of 0.05 M sodium tartrate (Sigma). The sub-
strate used was naphthol AS-BI phosphate (Sigma). The
number of TRAP-positive mono and multi nuclear cells
was counted using an eyepiece graticule at a magnification
of ×100.
Selection of genes for study
NFATc1, c-jun [34], RANK [35], TRAF6 [36], p38, NF-κB,
and c-Fos [37] are well known to play an important role
in osteoclastogenesis. It has recently been shown that sig-
nals other than those transmitted by RANKL and M-CSF
are required for osteoclastogenesis, and DAP12 [38] and
FcγRIIB [39] are key molecules in this respect. Gab2 is a
novel downstream effector of RANKL signalling [40].
Pim-1 was chosen because it interacts directly with human
NFATc1 [41], and it was thought that it may play a role in
the mouse signalling pathway.
Extraction of RNA and quantitative RT-PCR
RNA was extracted using a Qiagen kit from control,
RANKL treated, and RANKL plus IL-10 treated cells that
had been incubated for 48 hours. The RNA was reverse
transcribed using a Sigma kit. Primers were designed using
Primer3 and their sequences are given below. Real-time
PCR was conducted with a Techne Quantica machine and
Quansoft software using the DNA-binding dye SYBR
Green (Sigma) for the detection of PCR products. For the
generation of standard curves, the corresponding cDNA
was cloned into pGEM-T Easy (Promega). The concentra-
tion of DNA plasmid stock was determined by the OD at
260 nm and agarose gel electrophoresis. Copy number for
each plasmid was calculated on these measurements. The
linear range of the assay was determined by the amplifica-
tion of log serial dilutions of plasmids from 500 to 5 ×
106. The progress of the PCR amplification was monitored
by real-time fluorescence emitted from SYBR Green dur-
ing the extension time. The cycles were 95°C for 15 min,
followed by 35 cycles of 95°C for 20 s, 58°C for 20 s, and
72°C for 20 s. At the end of each PCR run, a melt curve
analysis was performed to show the absence of non-spe-
cific bands. For each sample, mRNA levels were expressed
as relative copy number normalised against β-actin
mRNA. This was achieved by constructing a standard
curve for each PCR run from serial dilutions of purified
plasmid DNA with specified amplicon. The mRNA copy
number was calculated for each sample from the standard
curves by the instrument's software. Samples were ana-
lysed in triplicate. For each sample copy number relative
to 106 β-actin copies in the same sample was calculated.
Primers used for PCR were as follows: NFATc1 sense, 5'-
CCGTTGCTTCCAGAAAATAACA-3'; NFATc1 antisense,BMC Cell Biology 2007, 8:4 http://www.biomedcentral.com/1471-2121/8/4
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5'-TGTGGGATGTGAACTCGGAA-3'; NFATc1 P1 isoform
sense, 5'-GCCAAGTACCAGCTTTCCAG-3'; NFATc1 P1
isoform antisense, 5'-AGGGTCGAGGTGACACTAGG-3';
NFATc1 P2 isoform sense, 5'-TTCGATTTCCTCTTC-
GAGTTC-3'; NFATc1 P2 isoform antisense, 5'-TGATT-
GGCTGAAGGAACAGC-3';  β-actin sense, 5'-
GTCATCACTATTGGCAACGAG-3';  β-actin antisense, 5'-
CCTGTCAGCAATGCCTGGTACAT-3', which yield prod-
ucts of 152, 185, 165, and 197 bp, respectively.
Immunofluorescence
Cells were grown on 2 mm glass coverslips in 6 well plates
for 48 hours with or without RANKL or RANKL plus IL-10.
The coverslips were then removed, washed in PBS, fixed in
4% paraformaldehyde/phosphate-buffered saline pH 7.2
for 15 minutes, washed in 70% alcohol and then air dried.
The cellular distribution of NFATc1 was assessed as fol-
lows. Cells were rehydrated through graded alcohols, per-
meablised with 0.1% Triton X-100, incubated with 1%
goat serum for 30 minutes to block non-specific binding
and then incubated with a specific mouse NFATc1 mono-
clonal (Santa Cruz Biotechnology, Heidelberg, Germany)
diluted 1:50 in 1% goat serum for 1 hour. The cells were
washed in PBS, incubated for 2 hours with a biotinylated
goat anti-mouse secondary (Vector Labs, Burlingame,
USA), washed in PBS and then incubated for 2 hours with
fluorescein conjugated streptavidin (Vector Labs, Burlin-
game, USA) Immunofluorescence was then visualised
using a Leica HC microscope. Photographs were taken
with a JVC TK C13603 digital camera linked to image pro
plus software at a magnification of ×400 or ×1000.
Statistical analysis
Differences between groups were assessed using Fisher's
analysis of variance (StatView version 5.01, Abacus Con-
cepts, Berkley, CA). A difference of p < 0.05 was consid-
ered significant.
Bioinformatics analysis
Information, including sequence data, on the genes dis-
cussed in this paper was obtained via the NCBI website
[42].
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